Results 51 to 60 of about 25,031 (288)

Case analysis of long-term negative psychological responses to psychedelics

Scientific Reports, 2023
Recent controversies have arisen regarding claims of uncritical positive regard and hype surrounding psychedelic drugs and their therapeutic potential. Criticisms have included that study designs and reporting styles bias positive over negative outcomes.
Rebecka Bremler, Nancy Katati, Parvinder Shergill, D. Erritzoe, R. Carhart-Harris   +4 more
semanticscholar   +1 more source

The Varieties of Psychedelic Law

SSRN Electronic Journal, 2022
After decades of prohibition, psychedelics are generating intense public and private interest. Scientists are researching the therapeutic properties of these substances, and mounting evidence supports their ability to treat a variety of mental health conditions.
openaire   +2 more sources

From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)

Scientific Reports
The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs.
R. Zeifman, M. Spriggs, Hannes Kettner, Taylor Lyons, F. Rosas, P. Mediano, D. Erritzoe, R. Carhart-Harris   +7 more
semanticscholar   +1 more source

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović, Kent W. Nilsson, Robert Fredriksson, Helgi B. Schiöth, Thiago C. Moulin   +4 more
wiley   +1 more source

Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring

Nature Communications
Psilocybin increases social connectedness and has strong clinical transdiagnostic efficacy for mental illness, making it a candidate treatment to reduce maternal disconnect, anxiety, and blunted affect seen in peripartum mood disorders.
Cassandra J. Hatzipantelis, Min Liu, Adam Love, Sadie J. Leventhal, Hero Maera, Srinidhi Viswanathan, Emily Avetisyan, Liana Belinsky, McKenna M. Rangel, Nina J. Jain, Max Kelly, Claire Copeland, Yara A. Khatib, Oliver Fiehn, David E. Olson, Danielle S. Stolzenberg   +15 more
doaj   +1 more source

Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment

Frontiers in Pharmacology
IntroductionCanine osteoarthritis (OA) is a prevalent disease characterized by progressive joint degeneration, pain, and impaired mobility. In older dogs, OA affects approximately 80% of the population.
Neide Maria Griebeler, Ricardo Penayo Cremonese, Yasmin Rafaela Fakih Correa, Priscila Romero Mazzini Pereira, Amanda Furjan Rial, Emanuela Leite, Maria Victoria Luz Gonçalves, Luiz Renato Marques das Almas, Nedice Borges Cardoso, Fernando Cezar-dos-Santos, Aline Theodoro Toci, Andrés Mojoli Le-Quesne, Francisney Pinto Nascimento   +12 more
doaj   +1 more source

Psychedelics: A new era of treatment?

European Psychiatry, 2021
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations.
S. Torres
doaj   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Psychedelics for Moral Bioenhancement in Healthy Individuals—A Violation of the Non-Maleficence Principle?

Psychoactives
Several authors have advanced the idea that psychedelics such as psilocybin might be effective means for achieving moral bioenhancement (MBE). Here, I discuss some reservations on this assertion from both neuropharmacological and bioethical perspectives,
Bor Luen Tang
doaj   +1 more source

Recreational Drug Use at a Music Festival: A Dual Approach Using Hair Biomarkers Analysis and Participant Self‐Reported Drug Use

Drug Testing and Analysis, EarlyView.
Combined self‐report and hair analysis in festival attendees (n = 249) revealed substantial discrepancies in drug use reporting, particularly for stimulants and dissociatives. This integrated approach enhances detection of poly‐drug use and provides a more reliable basis for monitoring and harm‐reduction strategies.
A. Y. Simão, T. Rosado, M. Barroso, M. Andraus, E. Gallardo   +4 more
wiley   +1 more source